Cargando…
Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease
INTRODUCTION: Study outcomes can be measured repeatedly based on the clinical trial protocol before randomization during what is known as the “run-in” period. However, it has not been established how best to incorporate run-in data into the primary analysis of the trial. METHODS: We proposed two-per...
Autores principales: | Wang, Guoqiao, Aschenbrenner, Andrew J., Li, Yan, McDade, Eric, Liu, Lei, Benzinger, Tammie L.S., Bateman, Randall J., Morris, John C., Hassenstab, Jason J., Xiong, Chengjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732759/ https://www.ncbi.nlm.nih.gov/pubmed/31517032 http://dx.doi.org/10.1016/j.trci.2019.07.007 |
Ejemplares similares
-
Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2018) -
Relationships between big‐five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease
por: Aschenbrenner, Andrew J., et al.
Publicado: (2020) -
Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease
por: Hassenstab, Jason, et al.
Publicado: (2021) -
Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease
por: Llibre-Guerra, Jorge J., et al.
Publicado: (2019) -
Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2022)